Form 4: United Therapeutics Director Receives Stock Options

United Therapeutics director Linda Maxwell was granted 3,650 stock options as part of an annual non-employee director award.

Summary

• Linda Maxwell, a director at United Therapeutics Corp (UTHR), acquired 3,650 stock options.
• The options were granted as an annual non-employee director award.
• The exercise price for these options is $306.41 per share.
• The options become exercisable on July 9, 2026, and expire on July 24, 2035.
• Following this transaction, Linda Maxwell beneficially owns 3,650 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director as part of annual compensation, which is a neutral to slightly positive event as it aligns director interests with long-term shareholder value.

Positives

• Director Linda Maxwell received an annual award of 3,650 stock options, aligning her interests with long-term shareholder value.

Risks

• The value of the stock options is subject to the future performance of United Therapeutics' common stock.
• If the stock price does not exceed the exercise price of $306.41, the options may expire worthless.

Future Outlook

The stock options granted to Director Linda Maxwell are exercisable starting July 9, 2026, and will expire on July 24, 2035, indicating a long-term incentive.

Industry Context

The granting of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries to incentivize long-term commitment and align interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice across publicly traded companies, including peers in the biotechnology sector such as Gilead Sciences (GILD) or Amgen (AMGN), aiming to align director incentives with shareholder returns.

Related Party Transactions

• The grant of stock options to Director Linda Maxwell constitutes a related party transaction, typical for director compensation.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director interests with shareholder value.

Next Steps

• The granted stock options will become exercisable on July 9, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Award